GKOS - Glaukos Corporation
NYSE
->
Healthcare
->
Medical Instruments & Supplies
San Clemente,
United States
Type: Equity
GKOS price evolution
GKOS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $72.81 | $48.35 | $99.32 | |
| Short term investments | $193.59 | $230.37 | $201.96 | |
| Net receivables | $56.41 | $51.22 | $46.55 | $39.85 |
| Inventory | $59.9 | $56.48 | $50.19 | $41.99 |
| Total current assets | $397.28 | $383.78 | $388.61 | $395.46 |
| Long term investments | ||||
| Property, plant & equipment | $168.27 | $169.63 | $172.12 | $174.54 |
| Goodwill & intangible assets | $341.81 | $348.05 | $349.09 | |
| Total noncurrent assets | $535.89 | $544.73 | $544.95 | |
| Total investments | $193.59 | $230.37 | $201.96 | |
| Total assets | $926.54 | $919.67 | $933.34 | $940.41 |
| Current liabilities | ||||
| Accounts payable | $11.1 | $11.56 | $12.75 | $13.44 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $71.68 | $70.08 | $72.24 | $74.01 |
| Long term debt | $126.47 | $156.61 | $383.52 | $383.74 |
| Total noncurrent liabilities | $184.43 | $410.37 | $404.63 | |
| Total debt | $156.61 | $383.52 | $383.74 | |
| Total liabilities | $258.03 | $254.52 | $482.61 | $478.65 |
| Shareholders' equity | ||||
| Retained earnings | -$711.86 | -$690.45 | -$639.9 | -$599.07 |
| Other shareholder equity | $2.62 | $2.19 | $1.44 | $1.17 |
| Total shareholder equity | $665.16 | $450.73 | $461.77 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.32 | $126.6 | $110.12 | $106.16 |
| Short term investments | $201.96 | $233.17 | $313.34 | $307.77 |
| Net receivables | $39.85 | $36.07 | $33.44 | $36.06 |
| Inventory | $41.99 | $37.84 | $23.01 | $15.81 |
| Total current assets | $395.46 | $443.86 | $486.13 | $469.44 |
| Long term investments | ||||
| Property, plant & equipment | $174.54 | $166.83 | $146.13 | $95.46 |
| Goodwill & intangible assets | $349.09 | $374 | $398.92 | $423.83 |
| Total noncurrent assets | $544.95 | $558.52 | $563.57 | $536.06 |
| Total investments | $201.96 | $233.17 | $313.34 | $307.77 |
| Total assets | $940.41 | $1002.38 | $1049.7 | $1005.5 |
| Current liabilities | ||||
| Accounts payable | $13.44 | $14.4 | $7.33 | $4.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $74.01 | $72.36 | $63.36 | $49.7 |
| Long term debt | $383.74 | $353.57 | $382.38 | $270.81 |
| Total noncurrent liabilities | $404.63 | $400.02 | $399.19 | $288.35 |
| Total debt | $383.74 | $382.48 | $382.38 | $270.81 |
| Total liabilities | $478.65 | $472.38 | $462.55 | $338.05 |
| Shareholders' equity | ||||
| Retained earnings | -$599.07 | -$464.41 | -$365.21 | -$310.06 |
| Other shareholder equity | $1.17 | -$2.98 | $0.01 | $1 |
| Total shareholder equity | $461.77 | $530 | $587.15 | $667.45 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $96.67 | $95.69 | $85.62 | $82.36 |
| Cost of revenue | $22.55 | $20.26 | $18.89 | |
| Gross Profit | $74.09 | $73.14 | $65.36 | $63.47 |
| Operating activities | ||||
| Research & development | $34.43 | $30.73 | $37.06 | |
| Selling, general & administrative | $66.19 | $61.98 | $63.03 | |
| Total operating expenses | $98.75 | $103.11 | $104.43 | $102.1 |
| Operating income | -$29.97 | -$39.07 | -$38.62 | |
| Income from continuing operations | ||||
| EBIT | -$46.86 | -$37.01 | -$33.29 | |
| Income tax expense | $0.18 | $0.33 | $0.38 | $0.06 |
| Interest expense | $1.04 | $3.35 | $3.45 | $3.43 |
| Net income | ||||
| Net income | -$21.41 | -$50.55 | -$40.84 | -$36.78 |
| Income (for common shares) | -$50.55 | -$40.84 | -$36.78 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $314.71 | $282.86 | $294.01 | $224.96 |
| Cost of revenue | $75.58 | $68.98 | $66.63 | $91.72 |
| Gross Profit | $239.14 | $213.88 | $227.38 | $133.24 |
| Operating activities | ||||
| Research & development | $138.77 | $123.27 | $101 | $85.39 |
| Selling, general & administrative | $224.07 | $192.93 | $179.26 | $171.4 |
| Total operating expenses | $367.84 | $296.2 | $260.26 | $256.79 |
| Operating income | -$128.7 | -$82.31 | -$32.87 | -$123.55 |
| Income from continuing operations | ||||
| EBIT | -$120.09 | -$84.71 | -$35.9 | -$118.2 |
| Income tax expense | $0.93 | $0.77 | $0.33 | -$11.97 |
| Interest expense | $13.63 | $13.72 | $13.37 | $14.12 |
| Net income | ||||
| Net income | -$134.66 | -$99.19 | -$49.59 | -$120.35 |
| Income (for common shares) | -$134.66 | -$99.19 | -$49.59 | -$120.35 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$50.55 | -$40.84 | -$36.78 | |
| Operating activities | ||||
| Depreciation | $10.06 | $9.98 | $9.62 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.31 | $11.16 | $12.99 | |
| Total cash flows from operations | -$18.37 | -$33.87 | -$10.66 | |
| Investing activities | ||||
| Capital expenditures | -$2.11 | -$0.97 | -$4.21 | |
| Investments | $38.01 | -$27.37 | -$7.68 | |
| Total cash flows from investing | $36.04 | $34.86 | -$29.38 | -$12.92 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.95 | $15.74 | $6.12 | |
| Net borrowings | -$0.23 | -$0.2 | -$0.19 | |
| Total cash flows from financing | $31.43 | $8.59 | $13.17 | $7.3 |
| Effect of exchange rate | -$0.09 | -$0.63 | -$0.89 | $0.82 |
| Change in cash and equivalents | $5.55 | $24.46 | -$50.97 | -$15.46 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$134.66 | -$99.19 | -$49.59 | -$120.35 |
| Operating activities | ||||
| Depreciation | $37.98 | $35.95 | $34.42 | $34.61 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.53 | $38.56 | $30.15 | $43.3 |
| Total cash flows from operations | -$57.76 | -$33.08 | $24.71 | -$22.99 |
| Investing activities | ||||
| Capital expenditures | -$20.25 | -$30.11 | -$47.78 | -$6.93 |
| Investments | $37.51 | $75.9 | -$8.37 | -$196.31 |
| Total cash flows from investing | $14.1 | $44.78 | -$58.23 | -$205.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $19.03 | $9.21 | $30.94 | $24.22 |
| Net borrowings | -$0.71 | -$0.53 | -$0.66 | $242.21 |
| Total cash flows from financing | $15.04 | $6.25 | $39.26 | $262.54 |
| Effect of exchange rate | $1.34 | -$1.47 | -$1.77 | -$0.09 |
| Change in cash and equivalents | -$27.28 | $16.48 | $3.96 | $34.41 |
News
Fundamentals
| Market cap | $8.44B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 55.09M |
| Revenue | $360.35M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$149.57M |
| Revenue Q/Q | 23.86% |
| Revenue Y/Y | 18.70% |
| P/E ratio | -56.43 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 23.42 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.71 |
|---|---|
| ROA | -16.08% |
| ROE | N/A |
| Debt/Equity | 1.04 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.54 |
| Quick ratio | 4.71 |